Lumida
/CLPT
⌘K
Clearpoint Neuro Inc

Clearpoint Neuro Inc

CLPT
$13.72USD↑+1.78%+0.24 today

MARKET CAP

418.5M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$13 – $14

52W RANGE

$8
$30

AI Summary

Stalk
StalkMedium

CLPT remains in a Stage 2 advancing corrective reset with clear higher highs and higher lows. Price is currently extended above rising short-term EMAs and in extreme overbought territory, and the late-June bearish exhaustion candle signals waning upside momentum and a likely pullback. Under a Speculative strategy, high asymmetry and defined structure are required, so patience is advised. A pullback toward the 9/21 EMA zone offers a more favorable entry for continuation participation.

  • ↑Q2 revenue $10.9M (+18% YoY), signaling sustained product demand.
  • ↑New 30k ft² lab (CAL) to expand capacity, targeting >$60M rev.
  • ↓H1 operational cash burn of $15M reduced cash reserves to $29.4M.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

ClearPoint Neuro, Inc. (NASDAQ: CLPT) is a pioneering player in the neurosurgery market, dedicated to advancing drug delivery systems for neurological disorders. The company focuses on integrating innovative technologies aimed at enhancing patient outcomes through minimally invasive neurosurgery. With a strategic emphasis on cell and gene therapy delivery, ClearPoint holds an established market position, collaborating with over 60 pharmaceutical partners and maintaining more than 175 active global centers. This positions ClearPoint as a key player within the burgeoning neurotherapeutics sector.

Bull says

  • ↑Q2 revenue $10.9M (+18% YoY), signaling sustained product demand.
  • ↑New 30k ft² lab (CAL) to expand capacity, targeting >$60M rev.
  • ↑60+ pharma partnerships—gene therapy tie-ups with Unicure underpin pipeline.
  • ↑Gross margin improved to 62%, benefiting from better inventory management.
  • ↑Manageable leverage and dividend policy support financial stability.
  • ↑R&D spending up 21% drives clinical support and long-term growth.

Bear says

  • ↓H1 operational cash burn of $15M reduced cash reserves to $29.4M.
  • ↓Q2 adjusted loss $0.38/share vs $0.29 estimate, missing expectations.
  • ↓Profitability remains negative despite 62% gross margin improvement.
  • ↓Analysts rate stock "Strong Sell", citing overvaluation concerns.
  • ↓High short interest signals broad skepticism limiting share upside.
  • ↓Execution risk rises if biopharma approval delays stall revenues.

Investment themes with CLPT

Health Care Equipment & Supplies↑ +0.40%

Clinical instruments and devices powering patient care

ABT · ISRG · SYK
Most Shorted Stocks↑ +0.54%

Stocks with highest short interest

LITE · FSLY · SPHR

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 05-15-2025neutral

Transcript signals

Bull points

  • Total revenue was $7.6 million for the 3 months ended March 31, 2024, and $5.4 million for the 3 months ended March 31, 2023, which represents 41% growth versus the first quarter of 2023.
  • 2024 is off to a great start for ClearPoint as we have made significant progress toward both financial operating goals as well as strategic product and partnership goals that will benefit the company in 2024 and beyond.
  • As we showed in Q1, we believe 2024 is going to be an exciting year as we earn new customers, grow same-store sales with new product launches and solidify important strategic partnerships with new and existing biotech partners. We expect to impact significantly more lives this year than in years past and we are thrilled to work at a company, which can impact so many patients in so many different ways.

Bear points

  • at this point, we're still early into the year. I don't think we're in a position to change the guidance. One reason is the early start, there's always things that can happen in the second half of the year. And number two, a big part of our growth here in Q1 came from kind of a nonrecurring capital component, which was a great start to the year, but we don't fully expect $1.4 million in capital sales every single quarter. It will likely be less than that in the quarters ahead. So that capital has to be replaced by something else.
  • at this point, we're still early into the year. I don't think we're in a position to change the guidance. One reason is the early start, there's always things that can happen in the second half of the year. And number two, a big part of our growth here in Q1 came from kind of a nonrecurring capital component, which was a great start to the year, but we don't fully expect $1.4 million in capital sales every single quarter. It will likely be less than that in the quarters ahead. So that capital has to be replaced by something else.
  • Functional neurosurgery navigation and therapy revenue consists of commercial sales of disposable products and services related to cases utilizing the ClearPoint system to deliver medical device therapy to the proper target and the ClearPoint Neuro PRISM laser applicators. This revenue segment declined 18% to $1.9 million for the first quarter of 2024. The decline in this segment was fully due to lower service revenue of $0.5 million.
Read full transcript analysis ›